This conference will bring together fundamental researchers and translational scientists to discuss recent successes and highlight challenges across the spectrum of emerging cellular therapeutics.
AsiaTIDES Oligonucleotide & Peptide Therapeutics is the only event in Asia bringing together science, technologies, and partners to accelerate oligonucleotide and peptide molecules to market.
ABRF is the largest international organization representing shared resource cores. With a focus on advanced technology, education and cutting-edge research in shared scientific resource core labs worldwide, the ABRF meeting is a collaborative hub for technological innovation, sharing best practices, and professional development.
The ECI “Delivery of Nucleic Acid Therapeutics: Biology, Engineering and Development” conference will provide a forum for increasing our mechanistic understanding of the biological processes underpinning non-viral and viral delivery, including molecular and cellular biology, virology, in vivo pharmacology and toxicology, rational optimization strategies, targeting, formulation, bioengineering and process development solutions to scale-up and manufacturing, regulatory considerations and preclinical and clinical NAT programs.
OPT brings together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process
For the past 19 years, the World Vaccine Congress Washington congress has evolved and grown into the leading vaccines congress globally, with: 350 speakers, 1500 attendees
The ASGCT mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease.
RNA Therapeutics Institute at UMass Medical School
The RTI was founded in 2009 and became an academic department in 2016, chaired by Phillip D. Zamore, Ph.D. The RTI is dedicated to leveraging the strong RNA biology and clinical research communities at UMMS to develop novel therapies for which RNA is the therapeutic target or modality.
United States 
